BioLineRx Ltd. (BLRX) Bundle
A Brief History of BioLineRx Ltd. (BLRX)
Foundation and Early Years
Foundation and Early Years
BioLineRx Ltd. was founded in 2002, in Jerusalem, Israel, establishing itself as a clinical-stage biopharmaceutical company focusing on the development of innovative therapeutics for cancer and other serious diseases. The company was publicly listed on NASDAQ under the ticker symbol BLRX in 2014.
Initial Public Offering (IPO)
During its IPO in 2014, BioLineRx raised approximately $15 million by offering 3.75 million American Depository Shares (ADS) at a price of $4.00 per ADS.
Strategic Partnerships and Collaborations
In 2016, BioLineRx entered into a collaboration with the University of California, San Diego (UCSD) to develop BI-1808, an immune-modulating agent for cancer treatment. This partnership aimed to leverage UCSD's expertise in immunotherapy.
Clinical Trials and Product Development
One of the company's lead products, BL-8040, a treatment designed for acute myeloid leukemia (AML), initiated a Phase 2 clinical trial in 2017. In 2020, the product showed promising results, demonstrating an overall response rate of 67% in patients, leading to further development and potential regulatory submissions.
Financial Performance and Market Presence
As of the end of Q2 2023, BioLineRx reported total assets of $40.5 million and liabilities amounting to $8.1 million, showcasing a solid balance sheet. The company's revenue for the same quarter reached $1.2 million, primarily from research grants and collaborations.
| Year | Revenue ($ millions) | Total Assets ($ millions) | Liabilities ($ millions) |
|---|---|---|---|
| 2018 | 0.5 | 18.7 | 4.5 |
| 2019 | 0.9 | 23.3 | 5.2 |
| 2020 | 1.1 | 30.1 | 6.3 |
| 2021 | 1.5 | 35.0 | 7.0 |
| 2022 | 1.0 | 38.0 | 7.5 |
| 2023 | 1.2 | 40.5 | 8.1 |
Recent Developments
In 2023, BioLineRx advanced its clinical pipeline with new trials for BL-8040 and commenced Phase 1 trials for BL-9090, targeting solid tumors. The company also reported a cash runway expected to extend into 2024, bolstered by a recent financing round raising $10 million.
Future Outlook
BioLineRx continues to focus on expanding its clinical trials and collaborations. The company aims to bring its promising therapies to market and expand its presence in the oncology market significantly. The projected market entry for key products like BL-8040 is estimated for 2025, contingent on regulatory approvals and clinical outcomes.
A Who Owns BioLineRx Ltd. (BLRX)
Ownership Structure
The ownership of BioLineRx Ltd. (BLRX) is characterized by a diverse structure of institutional and retail investors. As of the latest available data, the following outlines the significant shareholders of the company:
| Shareholder Type | Ownership Percentage | Number of Shares Held |
|---|---|---|
| Institutional Investors | 47.2% | 18,900,000 |
| Insider Ownership | 5.3% | 2,100,000 |
| Retail Investors | 47.5% | 19,100,000 |
Major Institutional Investors
Key institutional investors contributing to the ownership of BioLineRx as of the latest report include:
| Institution | Ownership Percentage | Number of Shares Held |
|---|---|---|
| The Vanguard Group, Inc. | 8.1% | 3,200,000 |
| BlackRock, Inc. | 7.6% | 3,000,000 |
| Wellington Management Company, LLP | 5.5% | 2,200,000 |
Insider Ownership
Insiders, including executive management and board members, own a portion of BioLineRx, indicating a vested interest in the company’s success. The breakdown includes:
| Insider Name | Position | Shares Owned |
|---|---|---|
| Dr. Kinneret Savitzky | CEO | 1,000,000 |
| Dr. Yossy Tzivion | Chairman | 600,000 |
| Mr. Shlomi Cohen | CFO | 500,000 |
Market Capitalization and Stock Performance
The overall financial health of BioLineRx can also be gauged through its market capitalization and stock performance metrics:
| Metric | Value |
|---|---|
| Market Capitalization | $105 million |
| Current Stock Price | $3.12 |
| P/E Ratio | N/A |
| 52-Week Range | $2.55 - $5.40 |
Recent Shareholder Activity
Recent shareholder activity involves significant changes in stock holdings by major players. Data shows:
- In the last quarter, The Vanguard Group increased its holdings by 15%.
- BlackRock reported a reduction in holdings by 10%.
- Insider purchases have been noted, with Dr. Kinneret Savitzky acquiring additional 200,000 shares.
Conclusion on Ownership Trends
The data reveals a significant presence of both institutional and retail investors in BioLineRx, alongside committed insider holdings. This distribution indicates a strong interest in the company's potential growth trajectory.
BioLineRx Ltd. (BLRX) Mission Statement
Corporate Vision
BioLineRx Ltd. aims to become a leader in the development of innovative therapeutics for cancer and other serious conditions. The company's mission is guided by a commitment to improving patient outcomes through cutting-edge research and development.
Core Values
- Innovation: Fostering a culture that prioritizes groundbreaking scientific advancements.
- Integrity: Conducting business ethically and responsibly.
- Collaboration: Partnering with leading researchers and organizations to accelerate therapeutic development.
- Patient-Centricity: Focusing on the needs and outcomes of patients in all aspects of operations.
Strategic Objectives
BioLineRx is focused on several key strategic objectives:
- Advancing the clinical development of its pipeline products.
- Enhancing partnerships with pharmaceutical companies for co-development opportunities.
- Maximizing shareholder value through strategic business decisions.
- Investing in research and development to address unmet medical needs.
Product Pipeline Overview
As of October 2023, BioLineRx has several products in various stages of development:
| Product Name | Indication | Development Stage | Expected Milestone |
|---|---|---|---|
| BL-8040 | Amyloidosis | Phase 2 | Final Results Q1 2024 |
| BL-7010 | Cancer | Phase 1 | Interim Results Q2 2024 |
| BL-1230 | Leukemia | Pre-Clinical | IND Application Q3 2024 |
Financial Performance
For the fiscal year ended December 31, 2022, BioLineRx reported the following financial metrics:
| Metric | Amount (USD) |
|---|---|
| Total Revenue | $5.2 million |
| Net Loss | $(10.3) million |
| Cash and Cash Equivalents | $15.1 million |
| Market Capitalization | $50.8 million |
Recent Achievements
In 2023, BioLineRx achieved several key milestones:
- Initiation of a Phase 2 trial for BL-8040 in combination with standard of care for amyloidosis.
- Successful completion of a $10 million financing round.
- Establishment of new collaborations with leading academic institutions.
Future Goals
Looking forward, BioLineRx is committed to:
- Expanding its clinical trials portfolio.
- Enhancing collaborations with biotech firms.
- Increasing investments in R&D to discover new therapies.
How BioLineRx Ltd. (BLRX) Works
Company Overview
Company Overview
BioLineRx Ltd. (NASDAQ: BLRX) is a biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company operates by identifying and developing a diverse pipeline of drug candidates through advanced scientific research and strategic collaborations.
Pipeline Development
BioLineRx's drug development pipeline is primarily focused on oncology. The pipeline includes:
- BL-8040: A first-in-class immunotherapy for treating acute myeloid leukemia (AML) and other cancers.
- BL-7010: An oral drug candidate targeting inflammatory bowel disease (IBD).
- BL-125: A novel cancer therapy currently in early-stage clinical trials.
Clinical Trials
As of the latest update, BioLineRx currently has several clinical trials in progress:
- BL-8040: Phase 2b trial in AML, with enrollment of approximately 100 patients.
- BL-7010: Phase 2 trial for IBD with a targeted enrollment of 150 patients.
| Drug Candidate | Indication | Clinical Phase | Patient Enrollment |
|---|---|---|---|
| BL-8040 | Acute Myeloid Leukemia | Phase 2b | ~100 |
| BL-7010 | Inflammatory Bowel Disease | Phase 2 | ~150 |
| BL-125 | Cancer | Early-stage | Ongoing |
Financial Performance
As of the end of 2022, BioLineRx reported the following financial metrics:
- Revenue: $2.8 million
- Net Loss: $13.6 million
- Cash and Cash Equivalents: $35 million
Strategic Collaborations
BioLineRx has engaged in partnerships to enhance its research and development capabilities:
- Collaboration with Teva Pharmaceutical Industries Ltd.: Focused on co-developing BL-8040.
- Partnership with the Hebrew University of Jerusalem: Research collaboration in various therapeutic areas.
Market Position and Stock Performance
As of October 2023, BioLineRx's stock performance has experienced fluctuations:
- Current Share Price: $3.15
- Market Capitalization: Approximately $100 million
- 52-Week Range: $1.90 - $4.50
How BioLineRx Ltd. (BLRX) Makes Money
Revenue Streams
Revenue Streams
BioLineRx Ltd. generates revenue primarily through collaborations and licensing agreements, along with potential product sales once their pipeline drugs receive regulatory approval.
Collaborative Agreements
The company enters into various collaborations with larger pharmaceutical firms. For instance, they have partnered with Novartis and other biotech companies to co-develop products.
| Partner | Collaboration Type | Financial Terms |
|---|---|---|
| Novartis | License Agreement | $5 million upfront, potential milestones of up to $50 million |
| Cleveland Clinic | Research Collaboration | Not disclosed |
| Other Biotech Firms | Co-Development | Variable, based on project |
Product Pipeline and Development
BioLineRx has an innovative pipeline with products in various stages of clinical trials.
| Product | Stage | Estimated Market Size |
|---|---|---|
| BL-8040 | Phase 3 | $2 billion |
| BL-7010 | Phase 2 | $500 million |
| BL-1258 | Preclinical | $1 billion |
Intellectual Property
The company holds several patents that protect their innovations, allowing them to negotiate lucrative licensing deals. Patent portfolio value as of 2023 is estimated at $30 million.
Grants and Funding
BioLineRx also benefits from government and private grants. In 2022, they received a grant of $1 million from the Israeli Innovation Authority.
Financial Performance
In their latest financial report, BioLineRx reported a total revenue of $4 million for the year ending December 31, 2022, a substantial increase from $2.5 million in 2021.
| Year | Total Revenue | Net Loss |
|---|---|---|
| 2022 | $4 million | $15 million |
| 2021 | $2.5 million | $12 million |
| 2020 | $3 million | $10 million |
Market Strategy
BioLineRx utilizes a target-driven approach, focusing on therapeutic areas with substantial unmet medical needs to ensure higher chances of securing partnerships and funding.
- Oncology
- Autoimmune Diseases
- Metabolic Disorders
BioLineRx Ltd. (BLRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support